ReviewHuman molecular genetics2025
Recent insights into the role of innate immunity in lupus.
Review in Human molecular genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Refining Human Phenotype Ontology (HPO) to enable better phenotype-genotype integration in systemic autoimmune rheumatic diseases.Orphanet journal of rare diseases · 2026Article
- Genetic Polymorphisms in Systemic Lupus Erythematosus and Their Clinical Implications: A Narrative Review.International journal of molecular sciences · 2026Review
- Systemic lupus erythematosus-driven accelerated atherosclerosis: the immune-metabolic-vascular axis and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder characterized by loss of self-tolerance to nucleic acids, resulting in multisystem inflammation and organ damage. The genetic underpinning of SLE spans from common risk variants with modest effect sizes to rare monogenic mutations with high penetrance. Recent advances in next-generation sequencing and transcriptomic profiling have illuminated the central role of innate immune pathways in disease pathogenesis. This review synthesizes emerging evidence regarding innate immunity in SLE, with emphasis on toll-like receptor (TLR) signaling and regulatory mechanisms, NLRP3 inflammasome activation, myeloid cell dysregulation, and microbiome-immune interactions. Understanding these pathways provides a foundation for developing targeted therapeutics that may offer precision medicine approaches for this heterogeneous disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.